An interventional study of SmartGUIDE (deflectable guidewire) and Any standard of care guidewire in Unruptured Cerebral Aneurysm, sponsored by Artiria Medical. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Artiria Medical · Not applicable, Interventional, and Other
The study was prematurely terminated following the successful EU CE marking of the device, which rendered the continuation of the investigation unnecessary. The study was not terminated for reasons related to participants' safety.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Intracranial Aneurysm with a site in France — 19 open to participants now, 26 under way, 1 of them phase 3. Intracranial Aneurysm · France.
Among the 66 studies in Intracranial Aneurysm with a site in France, this one is the 23rd largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2025, is one of 18 with no phase, and was the 61st registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →19 of the 66 studies in Intracranial Aneurysm with a site in France are open now. Recruiting first, the newest first:
Resolve Stroke · Sites in France
Ages 18+
CHU de Reims · Sites in France
Ages 18+
Sim&Cure · Sites in France
Ages 18+
Phenox GmbH · Sites in France, Germany, Italy and 2 more countries
Hospices Civils de Lyon · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 104 across 208 interventional studies indexed under Intracranial Aneurysm.
Median enrollment 171 across the 23 interventional studies, 206 across the 43 observational. Of the 37 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 66 have an industry lead sponsor. The 10 most frequent:
Artiria Medical is the lead sponsor of 3 studies on the registry; none are open to participants now.
Artiria Medical has 3 studies filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
4 of the studies in Intracranial Aneurysm with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04192955Phase 3University of CalgaryEvaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms | 2027-03 |
| NCT07864389Resolve StrokeMultimodal Approach Feasability Study for Untreated and Unruptured Intracranial Aneurysms | 2026-11 |
| NCT06940934Acandis GmbHPost-Market Product Surveillance of Intracranial ANeurysms Treated With Commercial ReGistered ACANDIS Devices in FrancE | 2026-12 |
| NCT06689410Nantes University HospitalMultimodal Biocollection Linked to the French Register of Intracranial Aneurysms | 2027-03-25 |
Add all 4 to your calendar (.ics) → With an account.
Among the 66 studies in Intracranial Aneurysm with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to confirm the safe and successful use of the SmartGUIDE guidewire, when used in neuro interventions. The performance of the SmartGUIDE guidewire in terms of safe and successful navigation within the neurovasculature will be compared to standard of care guidewire on the market.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: SmartGUIDE (deflectable guidewire)
Device: Any standard of care guidewire
SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
Performance
Intra-procedural technical success defined as successful navigation of device to the target vessel without need for shaping by hand, removal or exchange.
Time frame: During index procedure
Usability
Usability data (shape retention, pushability, trackability, navigability, support, proximal access complexity) collected through questionnaire.
Time frame: During index procedure
Procedural times
Procedural times (duration of tip reshaping, duration of access to target, duration of fluoroscopic exposition).
Time frame: During index procedure
Intra-procedural adverse events
Occurrence of adverse events.
Time frame: During index procedure and up to 48 hours post procedure
Intra-procedural device deficiencies
Occurrence of intra-procedural device deficiencies.
Time frame: During index procedure
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Jul 2026, 13 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2026 → Jul 2026 and completion Dec 2026 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
The study was prematurely terminated following the successful EU CE marking of the device, which rendered the continuation of the investigation unnecessary. The study was not terminated for reasons related to participants' safety.
The study was prematurely terminated following the successful EU CE marking of the device, which rendered the continuation of the investigation unnecessary. The study was not terminated for reasons related to participants' safety.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.